Tarsus Pharmaceuticals, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Tarsus Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Tarsus Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$25.2M, a 38.5% increase year-over-year.
  • Tarsus Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$141M, a 23.6% decline year-over-year.
  • Tarsus Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$143M, a 128% decline from 2022.
  • Tarsus Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$62.7M, a 416% decline from 2021.
  • Tarsus Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$12.2M, a 55% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$143M -$80.4M -128% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 -$62.7M -$50.6M -416% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 -$12.2M +$14.8M +55% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-17
2020 -$27M -$22.7M -528% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-14
2019 -$4.3M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.